HCPCS Level II code

J7517Mycophenolate mofetil, oral, 250 mg

HCPCS Level IIVerified Sep 5, 2026

Medicare payment

No national Medicare fee schedule we hold prices J7517 — the Physician Fee Schedule lists it with status indicator E (2026 file). CMS fee schedules ↗

Code definition

Code

J7517

Code system

HCPCS Level II

Full description

Mycophenolate mofetil, oral, 250 mg

Policy activity for HCPCS J7517

CLV Intelligence is tracking 2 policy changes that cite HCPCS J7517 most recently on 2026-08-04, drawn from 2 FDA notices. The changes span Multi-specialty. 1 is flagged critical or high priority.

FDA notices
2

Counts reflect the source documents CLV has matched to HCPCS J7517 to date; each links to the government publication that is authoritative. Monitored daily from CMS, the Federal Register, and Medicare Administrative Contractor publications.

Recent policy changes matched to J7517

Matched to this code by CLV analysis of each policy. The linked source document is authoritative.

FDA Approval: CELLCEPT (MYCOPHENOLATE MOFETIL) — Type 1 - New Molecular Entity

Multi-specialty

Government source· FDAverify ↗
Subscribe to view
See all alerts for J7517

Search J7517 across all alerts

Full history of CMS and MAC policy changes matched to this code.

Search all alerts →

Audit documentation

Building an audit file that includes HCPCS J7517?

The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

See audit packs — $349One-time purchase · not a subscription

Get alerts when policy changes affect J7517

Free weekly digest — no subscription required.

Get the free 90-day policy snapshot for your specialty

Free — no account required

See what CLV monitors for your specialty

Get a free 90-day sample snapshot — a PDF of every CMS and MAC policy change we tracked for your specialty and jurisdiction in the last quarter. Delivered instantly.

90-day windowPDF sample reportInstant download

By downloading, you agree to receive related policy update emails. You can unsubscribe at any time. Privacy policy